Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a license for US patents and Leqselvi launch in the US market.

Shares of Sun Pharmaceutical Industries climbed nearly 3 per cent on Tuesday after the firm said it has inked a settlement pact with US-based Incyte Corporation regarding Leqselvi, a drug used for ...

Sun Pharmaceutical Industries said that it has launched hair-loss treatment drug LEQSELVI (deuruxolitinib) in the U.S.

Indian drugmaker Sun Pharmaceutical Industries together with its subsidiaries announced that further to its intimation dated ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

Shares of Sun Pharma rose 2 percent to Rs 1,711 in morning trade on July 15, extending their gains for a third straight ...

In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte ...

Indian equity indices, Sensex and Nifty, are expected to open on flat-to-higher note on Tuesday following positive global ...

Shares of HDFC Life Insurance, HDB Financial, ICICI Lombard, Just Dial will remain in focus as companies will declare Q1 ...

GAIL signs long-term LNG agreement, Sun Pharma settles litigation, LIC appoints new CEO, Tata Group's green steel project ...